Sugi Predict

Sugi Predict / Compounds / SCHEMBL408415

SCHEMBL408415

SCHEMBL408415

CSc1ccc(CNc2ccc3nc(-c4ccccc4F)nc(Nc4ccncc4)c3c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ POLB P06746 2/20 0.48
▸ MEN1 O00255 6/20 0.47
▸ KMT2A Q03164 6/20 0.47
▸ USP1 O94782 3/20 0.47
▸ WDR48 Q8TAF3 3/20 0.47
▸ LMNA P02545 6/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ CYP1A2 P05177 5/20 0.46
▸ CYP3A4 P08684 5/20 0.46
▸ CYP2C19 P33261 4/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ CLK4 Q9HAZ1 3/20 0.46
▸ CYP2D6 P10635 3/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ USP2 O75604 2/20 0.46
▸ TP53 P04637 2/20 0.45
▸ CYP2C9 P11712 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409822 0.88 MEN1 (0.52) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL412579 0.82 MEN1 (0.53) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL1058063 0.81 MEN1 (0.52) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL14262819 0.79 MEN1 (0.53) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL4082133 0.78 MEN1 (0.55) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL1063104 0.76 MEN1 (0.57) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL411787 0.75 MEN1 (0.74) MAPTMAPK1POLBMEN1KMT2A
Ammonia Solution, Strong SCHEMBL3488927 0.73 MEN1 (0.55) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL27468710 0.73 LMNA (0.48) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL408416 0.73 LMNA (0.49) MAPTMAPK1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1107959-B1 QUINAZOLINE DERIVATIVES AS MEDICAMENTS SCIOS INC (US) 2006-10-11 — — EP claimed
US-20050171123-A1 Quinazoline derivatives as medicaments SCIOS, INC. 2005-08-04 — — US claimed
US-6903096-B2 Quinazoline derivatives as medicaments SCIOS, INC. (US) 2005-06-07 — — US claimed
CN-1152867-C Quinazoline derivatives as medicaments �����ɷ� 2004-06-09 — — CN claimed
US-20030069248-A1 Quinazoline derivatives as medicaments CHAKRAVARTY SARVAJIT (US) 2003-04-10 — — US claimed
US-20020161010-A1 Quinazoline derivatives as medicaments CHAKRAVARTY SARVAJIT (US) 2002-10-31 — — US claimed
JP-2002523502-A — — 2002-07-30 — — JP claimed
CN-1333757-A Quinazoline derivatives as medicaments SCIOS INC (US) 2002-01-30 — — CN claimed
US-6277989-B1 USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS SCIOS, INC. 2001-08-21 — — US claimed
EP-1107959-A2 QUINAZOLINE DERIVATIVES AS MEDICAMENTS SCIOS INC. (US) 2001-06-20 — — EP claimed
US-6184226-B1 ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS SCIOS INC. 2001-02-06 — — US claimed
WO-2000012497-A2 QUINAZOLINE DERIVATIVES AS MEDICAMENTS SCIOS INC. (US) 2000-03-09 — — WO claimed
US-20140120621-A1 TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING THE GENERAL HOSPITAL CORPORATION (US) 2014-05-01 — — US disclosed
US-8603818-B1 TGF-beta receptor inhibitors to enhance direct reprogramming THE GENERAL HOSPITAL CORPORATION (US) 2013-12-10 — — US disclosed
US-8298825-B1 TGF-beta receptor inhibitors to enhance direct reprogramming THE GENERAL HOSPITAL CORPORATION (US) 2012-10-30 — — US disclosed
US-20120021519-A1 EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) 2012-01-26 — — US disclosed
US-20060182716-A1 Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same ALIOS BIOPHARMA, INC. 2006-08-17 — — US disclosed
WO-2005110455-A2 COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION INTERMUNE, INC. (US) 2005-11-24 — — WO disclosed
WO-2004105684-A2 COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS INTERMUNE, INC. (US) 2004-12-09 — — WO disclosed
US-20030225089-A1 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161010-A1 Quinazoline derivatives as medicaments SMAD3, SMAD2, TGFBR1 MAPT 4399/4885MAPK1 4/4885POLB 4577/4885
US-20030225089-A1 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors CHRM3, CHRM2, CHRNB1 MAPT 623/4885MAPK1 12/4885POLB 2969/4885
US-20060182716-A1 Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same IFNAR1, IDE, CTSC MAPT 4401/4885MAPK1 3666/4885POLB 1586/4885
US-20050171123-A1 Quinazoline derivatives as medicaments TGFBR2, SMAD2, ADRB2 MAPT 4024/4885MAPK1 7/4885POLB 4287/4885
US-20030069248-A1 Quinazoline derivatives as medicaments SMAD3, SMAD2, TGFBR1 MAPT 4399/4885MAPK1 4/4885POLB 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.